Please assess the completion status of the following clinical trial:

Trial Title: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Subject Inclusion Criteria:~* Patients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:~  * Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high risk for relapse including:~    * Detectable minimal residual disease by either multicolor flow cytometry or by genomic assay after initial induction therapy~   * t(9;22) or detected BCR-ABL1 translocation by genomic methodologies~   * BCR-ABL1-Like B-ALL \[23\] including mutations of IKZF1 or CRLF2~   * Translocations or mutations involving 11q23 (MLL) gene.~   * Hypodiploid karyotype~   * Deletion of 9p~   * Loss of 17p or TP53 mutation~   * T-lymphocyte lineage antigen expression (T-ALL)~   * Prior CNS or other extramedullary involvement~   * WBC count ≥ 100,000 cells/μL at diagnosis~   * Acute biphenotypic or bilineal leukemia in CR1~ * Acute myeloid leukemia (AML) in CR1 with~    * Detectable minimal residual disease (MRD) by either multicolor flow cytometry or by genomic assay after initial induction therapy~   * In the absence of MRD any intermediate or high risk features according to the European LeukemiaNet 2017 guidelines indlucing:~* Mutated FL T3-ITD or FL T3-TKD~* Cytogenetic abnormalities not classified as favorable~* Cytogenetic abnormalities associated with myelodysplastic syndrome including abnormalities of chromosome 5, 7, or 17p~* Complex karyotype or monosomal karyotype~* t(9;11)(p21.1;q23.3); MLL-KMT2A or other rearrangements of KMT2A~* t(9;11); BCR-ABL1~* Inversions or translocations of chromosome 3~* T(6;9)(p23;q34.1); DEK-NUP214~* Somatic mutation of RUNX1, ASX1 or TP53~  * Extramedullary involvement~ * WBC count ≥100,000 cells/μL at diagnosis~    * Relapsed acute leukemia with ≤ 5% blasts in the bone marrow prior to transplantation (i.e. CR2 or greater).~   * Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with ≤ 10% blasts and at least one of the following:~ * Revised International Prognostic Scoring System risk score of INT, HIGH, or VERY HIGH at the time of transplant evaluation.~ * Life-threatening cytopenias~ * Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.~ * Therapy related disease or disease evolving from other malignant processes.~    * Chronic myelomonocytic leukemia (CMML) with ≤ 10% blasts prior to transplantation.~   * Chronic myeloid leukemia (CML) meeting one of the following criteria:~ * Failed or are intolerant to BCR-ABL tyrosine kinase inhibitors.~ * CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g. T351I mutation).~ * CML with accelerated or blast phase with \<10% blasts after therapy.~    * Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria~   * Hodgkin lymphoma meeting both of the following criteria:~ * Responding to therapy prior to enrollment~ * Relapse after autologous bone marrow transplant or are ineligible for autologous bone marrow transplant.~    °Non-Hodgkin lymphoma meeting both of the following criteria:~ * Responding to therapy prior to enrollment.~ * Relapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant.~ * Patients aged from birth through 65 years old are eligible.~ * Patients must have Karnofsky/Lanksy performance status ≥70%.~ * Cardiac left ventricular ejection fraction ≥50% at rest.~ * Serum bilirubin ≤ 2 mg/dL. Patients with Gilbert's disease or ongoing hemolytic anemia are acceptable if the direct bilirubin is ≤ 2 mg/dL.~ * AST and ALT ≤ 2.5 x ULN unless thought to be disease related~ * Estimated or measured creatinine clearance \> 50 mL/min/1.73 m\^2 body surface area.~ * Adult patients and pediatric patients capable of performing pulmonary function studies must have hemoglobin adjusted pulmonary DLCO ≥50% of predicted.~Subject Exclusion Criteria:~* Persons with a HLA matched sibling donor or a 8/8 allele level HLA-matched unrelated donor.~* Female patients who are pregnant or breast-feeding.~* Persons with an infection that is not responding to antimicrobial therapy.~* Persons who are seropositive for HIV.~* Persons with active/detectable central nervous system malignancy.~* Persons who do not meet the age and organ function criteria specified above.~* Presence of psychiatric or neurologic disease, or lack of social support that limits the patient's ability to comply with the treatment protocol including supportive care, followup, and research tests.~* Prior allogeneic hematopoietic cell transplantation are ineligible.~* Patients with history of other malignancy within 5 years of study therapy are ineligible with the following exceptions: Low grade prostate cancer (Gleason's ≤6) treated with curative intent, breast ductal carcinoma in situ treated with curative intent, or nonmelanomatous skin carcinomas.~Donor Inclusion and Exclusion Criteria:~* Partially HLA-matched unrelated volunteers (allele level matched at 6-7 of 8 HLA loci: -A, -B, -C, and -DRB1) are eligible.~* Related, haploidentical donors are eligible.~* Able to provide informed consent to the donation process~* Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Radiation, Thiotepa & Cyclophosphamide (Type: EXPERIMENTAL): None
- Busulfan, Fludarabine & Melphalan (Type: EXPERIMENTAL): None
- Clofarabine, Thiotepa & Melphalan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).